newsfilter
← Latest News
Business Wire·

OncoResponse Secures Investment from Baxalta

HOUSTON & BANNOCKBURN, Ill.--(BUSINESS WIRE)--OncoResponse, an immuno-oncology antibody discovery company, today announced an investment from Baxalta Incorporated (NYSE: BXLT). In October 2015, OncoResponse closed a Series A financing co-led by ARCH Venture Partners, Canaan Partners and MD Anderson, with William Marsh Rice University and Alexandria Real Estate Equities also participating. The investment by Baxalta brings the total Series A to $12.5 million and will be used to support OncoResponse’s ongoing efforts to interrogate the humoral response of elite responders to cancer immunotherapy to identify antibodies and potential targets for novel therapeutic development.